Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Sells $48,782.16 in Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada sold 38,716 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $48,782.16. Following the completion of the sale, the chief financial officer now owns 50,566 shares of the company’s stock, valued at $63,713.16. The trade was a 43.36 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Regulus Therapeutics Trading Down 3.1 %

Regulus Therapeutics stock opened at $1.24 on Friday. Regulus Therapeutics Inc. has a 1 year low of $1.13 and a 1 year high of $3.79. The company’s 50-day moving average is $1.52 and its two-hundred day moving average is $1.58. The company has a market cap of $81.22 million, a PE ratio of -1.16 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Research analysts forecast that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.80.

Institutional Investors Weigh In On Regulus Therapeutics

A number of institutional investors have recently made changes to their positions in RGLS. JPMorgan Chase & Co. increased its stake in shares of Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 52,059 shares during the last quarter. Barclays PLC raised its holdings in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 62,549 shares during the period. Jane Street Group LLC bought a new stake in shares of Regulus Therapeutics in the 3rd quarter valued at $46,000. State Street Corp grew its stake in Regulus Therapeutics by 3.5% in the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock valued at $1,572,000 after acquiring an additional 33,496 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in shares of Regulus Therapeutics in the third quarter worth about $1,403,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.